Physician profile
Krishdeep Khosla
NPI 1306899570
$4,182.09
in general payments reported to CMS, 2019-2025
27 companies · $1,005 in 2025
The $1,005 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $491 · 2021: $682 · 2022: $290 · 2023: $426 · 2024: $557 · 2025: $1,005.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $696.10 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $633.65 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $497.88 | 2023-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals Lp | $321.06 | 2019-2025 | Airsupra |
| Astellas Pharma US INC | $214.59 | 2021 | |
| Novartis Pharmaceuticals Corporation | $214.40 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $202.80 | 2025 | Neffy |
| Abbvie INC. | $181.25 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $148.25 | 2022-2025 | |
| Horizon Therapeutics Plc | $146.41 | 2023 | Krystexxa |
| Sumitomo Pharma America, INC. | $120.34 | 2023-2024 | Aptiom |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.40 | 2020-2025 | Caplyta |
| Dexcom, INC. | $103.44 | 2023 | Dexcom G7 Gss (161) |
| Otsuka America Pharmaceutical, INC. | $76.44 | 2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Pfizer INC. | $64.12 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amphastar Pharmaceuticals, INC. | $64.08 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $57.83 | 2022-2025 | Daybue |
| Nestle Healthcare Nutrition INC. | $56.25 | 2020-2021 | |
| Exact Sciences Corporation | $48.84 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Jazz Pharmaceuticals INC. | $35.87 | 2025 | |
| Kaleo, INC. | $35.26 | 2024 | Auvi-Q |
| Bavarian Nordic A/S | $31.15 | 2025 | Vivotif |
| Lilly USA, LLC | $28.63 | 2021-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $24.26 | 2024 | Proclaim |
| Kyowa Kirin, INC. | $24.15 | 2025 | |
| Lundbeck LLC | $23.70 | 2025 | Rexulti |
| Ferring Pharmaceuticals INC. | $20.94 | 2025 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishdeep Khosla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.